Alnylam Pharmaceuticals (ALNY) Financial Analysis & Valuation | Quarter Chart
Alnylam Pharmaceuticals (ALNY)
ALNYPrice: $442.7
Fair Value: 🔒
🔒score
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hep... more
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and ... more
Description
Shares
| Market Cap | $58.49B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Yvonne L. Greenstreet |
| IPO Date | 2004-06-01 | CAGR | — |
| Employees | 2,230 | Website | www.alnylam.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ALNY chart loading...
Fundamentals
Technicals
| Enterprise Value | $59.88B | P/E Ratio | 1475.67 |
| Forward P/E | 22.68 | PEG Ratio | — |
| P/S Ratio | 16.57 | P/B Ratio | 228.12 |
| P/CF Ratio | 200.7 | P/FCF Ratio | 240.36 |
| EPS | $0.3 | EPS Growth 1Y | -109.16% |
| EPS Growth 3Y | -102.46% | EPS Growth 5Y | -103.07% |
| Revenue Growth 1Y | 53.24% | Gross Margin | 0.51% |
| Operating Margin | 0.08% | Profit Margin | 0.01% |
| ROE | 0.26% | ROA | 0.01% |
| ROCE | 0.08% | Current Ratio | 2.54 |
| Quick Ratio | 2.49 | Cash Ratio | 0.96 |
| Debt/Equity | 5.59 | Interest Coverage | 3.6 |
| Altman Z Score | 6.94 | Piotroski Score | 5 |